OrbiMed Advisors focuses on investments in the global healthcare industry. The firm invests across the spectrum of life sciences companies from early-stage private biotechnology companies to large, publicly-traded pharmaceutical companies. OrbiMed Advisors manages investments across three strategies: mutual funds, hedge funds and private equity funds. The firm is also known to engage in shareholder activist investment strategies.OrbiMed Advisors' hedge fund strategy invests both long and short in the health sciences sector. OrbiMed employs a global investment approach that provides a broad opportunity set and reduced volatility through diversification. They take long positions primarily in small-cap and mid-cap companies with products with the potential for future 'blockbuster' potential.OrbiMed Advisors' mutual funds also invest globally in health sciences companies. Funds under management include the Eaton Vance Worldwide Health Sciences Fund and the Finsbury Worldwide Pharmaceutical Trust. The Eaton Vance Worldwide Health Sciences Fund is a publicly-offered open-end mutual fund that invests globally in biotechnology and pharmaceutical investment opportunities. The Finsbury Worldwide Pharmaceutical Trust is a closed-end UK Investment Trust which also invests globally in biotechnology and pharmaceutical investment opportunities.The firm's private equity activities focus drug discovery, drug development and medical device companies. The firm invests across all stages of company development with particular emphasis on mid- and later-stage private companies. OrbiMed Advisors is generally the lead investor in their portfolio companies and often takes an active role on those companies' boards of directors.

Consonance Capital Management's (CCM) funds seek to deliver exceptional, uncorrelated risk adjusted returns. CCM seeks to meet this objective by focusing on investment opportunities in the publicly traded stocks of healthcare companies. The firm invests in all sub-sectors of the healthcare sector including healthcare information technology, managed care, pharmaceuticals, specialty pharmaceuticals, commercial stage biotechnology, healthcare facilities and services, medical devices and supplies, diagnostics and consumer-based healthcare companies.CCM believes the public healthcare market lends itself to an active long/short strategy. The firm focuses on creating long and short portfolios driven by the opportunity for absolute return and alpha creation. The funds also invest in other types of securities and may use a variety of investment techniques to generate profit and/or control risk. These may include participating in swaps, buying or selling futures contracts, purchasing and writing options and other derivative contracts, purchasing or selling debt instruments, and trading on margin by borrowing funds and pledging securities as collateral. CCM invests primarily in healthcare companies in the US, and on an opportunistic basis in the rest of the world.^

JCM offers U.S. equity, global & international equity, fixed income, asset allocation and alternative investment strategies. The firm also offers investment strategies through affiliated investment advisors. The firm seeks to add value versus benchmarks by actively pursuing alpha generation through proprietary fundamental research. They look for companies with misunderstood fundamentals and price dislocations, as well as rapidly growing companies for some equity strategies. For their equity strategies, JCM favors businesses with sustainable above-average earnings growth potential, outstanding free-cash flow generation, recurring revenue and strong profit margins and return on invested capital. The firm's fixed-income research focuses on businesses that have strong or improving balance sheets, improving free-cash flow generation and recurring revenue. They use a proprietary fixed-income risk management tool named Quantum which allows them to view relative value, risk and returns at the portfolio level, individual credit level and across the investable credit universe globally.

Wellington Management Co. LLP (Private Equity) focuses in companies located in US. The firm invests in consumer discretionary, technology, financial services, biotech, and health care. They provide capital for growth and later stage capital requirement.

Fidelity Management & Research Co.'s (FMR) investment approach is based on a rigorous, fundamental, bottom-up stock selection process. The firm seeks to identify and invest in the stocks of companies with the potential for long-term capital appreciation or companies with hidden or unrealized value.FMR uses a wide variety of investment strategies in managing client assets, including, but not limited to, investments in: stocks and other equity securities; stocks with growth or value characteristics; bonds and other debt securities and repurchase agreements for those securities; and real estate related investments. The firm may participate in short sales, margin transactions, and option writing, including covered options, uncovered options or spreading strategies. FMR invests in US and non-US issuers, including issuers in emerging or frontier markets. They invest in companies with small, medium and large market capitalizations. Investments are allocated across different asset classes, market sectors, maturities, countries, and regions. Investments may be made in the securities of companies engaged in particular industries or market sectors and in a combination of underlying Fidelity funds.Margin may be required in connection with certain client futures and options transactions or in connection with short sales. FMR does not engage in the purchase of securities on margin, except in connection with the clearance and settlement of securities transactions.FMR may engage in swap transactions and swaptions, including interest rate, total return and credit default; written covered call options; and futures transactions, currency spot and forward trading and other currency related derivatives. In addition, FMR may engage in securities lending to parties such as broker-dealers or other institutions.

OrbiMed focuses exclusively on global investments across the entire spectrum of private and publicly-traded life sciences companies. They seek to invest in the most promising investment opportunities regardless of a company's stage of development. The firm invests at all stages of development from private start-ups and university spinouts to the largest global pharmaceutical companies. OrbiMed focuses on companies involved in drug development, drug discovery and medical devices, with particular emphasis on mid-stage private companies. Investments typically range from $5 million to $40 million. OrbiMed is generally a lead investor and takes an active role on their portfolio companies' boards of directors